Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of FDL169 in Healthy Volunteers
NCT02359357Phase 1Completed
- Sponsor
- Flatley Discovery Lab
- Start
- Jan 2015
- Primary completion
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of FDL169 in cystic fibrosis (CF) (4 arms), sponsored by Flatley Discovery Lab. Primary endpoints: Safety and tolerability following single oral doses of FDL169 at 48 hours, Food effect on the tolerability of FDL169 at 48 hours and 2 more. Started Jan 2015; status: completed.
02
Drugs
FDL169
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT02359357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02359357.